5.20

1.17% 0.06

After Hours: 5.20

Abcellera Biologics Inc (ABCL)

Overview News Price History Option Chain Financials Why ABCL Down? Discussions Forecast

Abcellera Biologics Inc stock is traded at $5.20, with a volume of 6.44M. It is up +1.17% in the last 24 hours and up +27.45% over the past month. AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.

Previous Close:

$5.14

Open:

$5.14

24h Volume:

6.44M

Relative Volume:

1.19

Market Cap:

$1.59B

Revenue:

$75.13M

Net Income/Loss:

$-146.41M

P/E Ratio:

-10.60

EPS:

-0.4904

Net Cash Flow:

$-174.43M

1W Performance:

+27.14%

1M Performance:

+27.45%

6M Performance:

+48.15%

1Y Performance:

+160.00%

1-Day Range:

$5.04

$5.43

1-Week Range:

$3.94

$5.43

52-Week Range:

$1.94

$6.515

Abcellera Biologics Inc Stock (ABCL) Company Profile

Name

Abcellera Biologics Inc

Sector

Healthcare (1108)

Industry

Biotechnology (618)

Phone

(604) 559-9005

Address

150 W 4TH AVENUE, VANCOUVER

Employee

562

Twitter

Next Earnings Date

2026-05-11

Latest SEC Filings

ABCL's Discussions on Twitter

Compare ABCL vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ABCL Abcellera Biologics Inc	5.20	1.57B	75.13M	-146.41M	-174.43M	-0.4904
VRTX Vertex Pharmaceuticals Inc	434.52	110.03B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	638.88	67.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	806.46	50.76B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	297.45	40.12B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	151.56	32.68B	742.00K	-1.37B	-1.07B	-7.0731

Abcellera Biologics Inc Stock (ABCL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-07-25	Downgrade	Leerink Partners	Outperform → Market Perform
Jul-07-25	Resumed	Leerink Partners	Outperform
Aug-20-24	Downgrade	The Benchmark Company	Buy → Hold
Feb-22-24	Upgrade	The Benchmark Company	Hold → Buy
Dec-05-23	Initiated	KeyBanc Capital Markets	Overweight
Nov-06-23	Downgrade	The Benchmark Company	Buy → Hold
Oct-13-23	Resumed	Piper Sandler	Overweight
Feb-28-23	Initiated	Cowen	Outperform
Dec-15-22	Initiated	Goldman	Buy
Nov-16-22	Initiated	Truist	Buy
Dec-21-21	Initiated	The Benchmark Company	Buy
Nov-19-21	Initiated	Piper Sandler	Overweight
Jan-05-21	Initiated	BMO Capital Markets	Outperform
Jan-05-21	Initiated	Berenberg	Buy
Jan-05-21	Initiated	Credit Suisse	Outperform
Jan-05-21	Initiated	SVB Leerink	Outperform
Jan-05-21	Initiated	Stifel	Buy

View All

Abcellera Biologics Inc Stock (ABCL) Latest News

May 24, 2026

Does AbCellera (ABCL) Have a Clear Path From ABCL635 Data to a Durable Business Model? - Yahoo Finance

May 24, 2026

May 22, 2026